by Market Overview
Transthyretin amyloid cardiomyopathy (ATTR-CM) or familial amyloid cardiomyopathy is a rare but fatal progressive heart condition caused due to mutation in the transthyretin (TTR) gene. ATTR-CM occurs when abnormal deposits of misfolded TTR protein called amyloid accumulate in the heart muscle. The symptoms include shortness of breath, fatigue, exercise intolerance and cardiac arrhythmias. Currently, limited treatment options are available to halt disease progression or improve survival. Drugs like tafamidis and inotersen aim to stabilize the TTR tetramer and reduce amyloid formation. However, there is a need for more effective and affordable therapies.
The Global Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Transthyretin Amyloid Cardiomyopathy Treatment Market Demand are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin, Silk€TMn, HoMedics USA LLC, PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial), among others. Major players are focusing on development of gene silencing drugs like RNA interference (RNAi) therapies, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA) to prevent abnormal TTR production.
The growing prevalence of ATTR-CM worldwide due to increasing life expectancy is a major factor fueling the demand. According to estimates, approximately 200,000 to 400,000 people are affected globally. Additionally, rising awareness about early diagnosis and availability of recent disease modifying treatments are boosting the market growth.
Key players are also expanding their geographical presence through acquisitions and collaborations to cater to the rising disease burden across countries. For instance, in 2021, Ionis Pharmaceuticals acquired its manufacturing partner through which it aims to commercialize novel gene silencing therapies for ATTR-CM in international markets.
Market Key Trends
One of the key trends in Transthyretin Amyloid Cardiomyopathy Treatment Market is the shift towards developing next generation therapies based on RNA interference (RNAi) technologies. RNAi therapies provide more targeted and permanent suppression of transthyretin (TTR) production. Companies are investing heavily in clinical research of RNAi drugs like revusiran, patisiran, and fitusiran which have shown safety and promising efficacy in reducing amyloid deposits and protein levels in ATTR-CM patients. Besides stabilizing the disease, RNAi based drugs are expected to emerge as a disease modifying option for ATTR-CM treatment in future.
Porter’s Analysis
Threat of new entrants: The large capital requirement and resources needed to conduct R&D pose barriers for new companies.
Bargaining power of buyers: Individual customers have low bargaining power due to lack of treatment options and life threatening nature of disease. However, large healthcare providers and institutional buyers have higher negotiating power.
Bargaining power of suppliers: Suppliers of raw materials and components have moderate bargaining power due to availability of substitute suppliers.
Threat of new substitutes: Potential new drug candidates and alternative treatment methods can pose threat over the long run.
Competitive rivalry: Intense competition exists among key players to develop innovative and cost effective treatment options.
Geographical Regions
North America dominates the global market in terms of value and is expected to continue its dominance over the forecast period. High awareness levels, advanced healthcare infrastructure and spending are key factors contributing to the large market size.
Asia Pacific region is poised to be the fastest growing market driven by large patient pools, rising disposable incomes, increasing focus of international players and improving healthcare scenarios. Countries like India, China and Japan are anticipated to offer attractive opportunities.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
